NCD110.21

 

ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN CANCER

AND RELATED NEOPLASTIC CONDITIONS

 

Effective Date of this Version

4/7/2008

 

Benefit Category

DRUGS AND BIOLOGICALS

Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.

 

Item/Service Description

 

General

• The ESAs stimulate the bone marrow to make more red blood cells and are United States Food and Drug Administration (FDA) approved for use in reducing the need for blood transfusion in patients with specific clinical indications.

• The FDA has issued alerts and warnings for ESAs administered for a number of clinical conditions, including cancer.

• Published studies report a higher risk of serious and life-threatening events associated with oncologic uses of ESAs.

 

Indications and Limitations of Coverage

 

Nationally Covered Indications

• The ESA treatment for the anemia secondary to myelosuppressive anticancer chemotherapy in solid tumors, multiple myeloma, lymphoma, and lymphocytic leukemia is only reasonable and necessary under the following specified conditions:

o The hemoglobin level immediately prior to initiation or maintenance of ESA treatment is <10 g/dL (or the hematocrit is <30%).

o The starting dose for ESA treatment is the recommended FDA label starting dose, no more than 150 U/kg/3 times weekly for epoetin and 2.25 mcg/kg/1 time weekly for darbepoetin alpha.

 Equivalent doses may be given over other approved time periods.

o Maintenance of ESA therapy is the starting dose if the hemoglobin level remains below 10 g/dL (or hematocrit is <30%) 4 weeks after initiation of therapy and the rise in hemoglobin is > 1g/dL (hematocrit > 3%).

o For patients whose hemoglobin rises <1 g/dl (hematocrit rise <3%) compared to pretreatment baseline over 4 weeks of treatment and whose hemoglobin level remains <10 g/dL after the 4 weeks of treatment (or the hematocrit is <30%), the recommended FDA label starting dose may be increased once by 25%.

 Continued use of the drug is not reasonable and necessary if the hemoglobin rises <1 g/dl (hematocrit rise <3 %) compared to pretreatment baseline by 8 weeks of treatment.

o Continued administration of the drug is not reasonable and necessary if there is a rapid rise in hemoglobin >1 g/dl (hematocrit >3%) over 2 weeks of treatment unless the hemoglobin remains below or subsequently falls to <10 g/dL (or the hematocrit is <30%).

 Continuation and reinstitution of ESA therapy must include a dose reduction of 25% from the previously administered dose.

o ESA treatment duration for each course of chemotherapy includes the 8 weeks following the final dose of myelosuppressive chemotherapy in a chemotherapy regimen.

 

Nationally Non-Covered Indications

• The ESA treatment is not reasonable and necessary for beneficiaries with certain clinical conditions, either because of a deleterious effect of the ESA on their underlying disease or because the underlying disease increases their risk of adverse effects related to ESA use.

o These conditions include:

 Any anemia in cancer or cancer treatment patients due to folate deficiency, B-12 deficiency, iron deficiency, hemolysis, bleeding, or bone marrow fibrosis.

 The anemia associated with the treatment of acute and chronic myelogenous leukemias (CML, AML), or erythroid cancers.

 The anemia of cancer not related to cancer treatment.

 Any anemia associated only with radiotherapy.

 Prophylactic use to prevent chemotherapy-induced anemia.

 Prophylactic use to reduce tumor hypoxia.

 Patients with erythropoietin-type resistance due to neutralizing antibodies.

 Anemia due to cancer treatment if patients have uncontrolled hypertension.

 

Other

• Local Medicare contractors may continue to make reasonable and necessary determinations on all other uses of ESAs not specified in this NCD.

• See the Medicare Benefit Policy Manual, chapter 11, section 90 and chapter 15, section 50.5.2 for coverage of ESAs for end-stage renal disease related anemia.

• (This NCD last reviewed July 2007.)

 

Claims Processing Instructions

• TN 1413 (Medicare Claims Processing)

 

Coverage Transmittal Link

• http://www.cms.gov/transmittals/downloads/R80NCD.pdf

 

National Coverage Analyses (NCAs)

• This NCD has been or is currently being reviewed under the National Coverage Determination process.

• The following are existing associations with NCAs, from the National Coverage Analyses database.

• Original consideration for Erythropoiesis Stimulating Agents (ESAs) for non-renal disease indications (CAG-00383N) opens in new window

 

NCD ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN CANCER AND RELATED NEOPLASTIC CONDITIONS